The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal ...

With its remote endovascular procedure system currently under review at the FDA, Microbot Medical has put forward positive ...

The market turbulence unleashed by President Donald Trump’s tariff policies will likely evaporate the trickle of biotech IPOs ...

The pair examine industry trends, company closures, developments in the cell and gene space—and the reductions in force ...

Kronos Bio is vacating its corporate headquarters amid a wider cost-cutting exercise for the struggling biotech. | Kronos Bio ...

In late March, Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. announced 10,000 layoffs across ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

Keros Therapeutics is considering whether it needs to find a buyer, while strengthening its stockholder rights as activist ...

Intuitive has snagged a clearance from the FDA for a surgical stapler system designed for its single-port robotic platform, ...

Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

Pfizer is officially bidding adieu to its sprawling research site in San Diego as it readjusts its local footprint and moves into a new site. | The company is moving its oncology R&D digs in San Diego ...

Unable to secure additional financing amid a stormy market, Tempest Therapeutics has put a call out for partners as it seeks ...